Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza

Influenza and other Respiratory Viruses

Volumn 2, Issue 6, 2008, Pages 193-202

  Ambrose, Christopher S ^a   Luke, Catherine ^b   Coelingh, Kathleen ^a  

^a MEDIMMUNE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Influenza; Live attenuated; Vaccine

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; LIVE VACCINE; PLACEBO; TRIPLE VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; AVIAN INFLUENZA; CELLULAR IMMUNITY; CHILL; CLINICAL TRIAL; COLD ACCLIMATIZATION; COMBINATION CHEMOTHERAPY; COUGHING; DECREASED APPETITE; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; FATIGUE; FEVER; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H9N2; INJECTION SITE IRRITATION; IRRITABILITY; LETHARGY; MONOTHERAPY; MYALGIA; NONHUMAN; NOSE CONGESTION; OTITIS MEDIA; PANDEMIC; PATIENT COMPLIANCE; PHENOTYPE; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVACCINATION; REVIEW; RHINORRHEA; SEASONAL VARIATION; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; SPUTUM; TEMPERATURE SENSITIVITY; VIRUS ATTENUATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; ADOLESCENT; ADULT; CHILD; EPIDEMIC; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MIDDLE AGED; PRESCHOOL CHILD; UNITED STATES;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA A VIRUS, H9N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; UNITED STATES; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 58149330583     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2008.00056.x     Document Type: Review

References (53)

1. Maassab HF. Plaque formation of influenza virus at 25 degrees C. Nature 1968; 219: 645-646.
2. Jin H, Lu B, Zhou H et al. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 2003; 306:18-24.
3. Jin H, Zhou H, Lu B, Kemble G. Imparting temperature sensitivity and attenuation in ferrets to A/Puerto Rico/8/34 influenza virus by transferring the genetic signature for temperature sensitivity from cold-adapted A/Ann Arbor/6/60. J Virol 2004; 78:995-998.
4. Chen Z, Aspelund A, Kemble G, Jin H. Genetic mapping of the cold-adapted phenotype of B/Ann Arbor/1/66, the master donor virus for live attenuated influenza vaccines (FluMist). Virology 2006; 345:416-423.
5. Hoffmann E, Mahmood K, Chen Z et al. Multiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/ 66. J Virol 2005; 79:11014-11021.
6. Kemble G, Greenberg H. Novel generations of influenza vaccines. Vaccine 2003; 21:1789-1795.
7. Murphy BR, Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 2002; 15:295-323.
8. Smith DB, Inglis SC. The mutation rate and variability of eukaryotic viruses: An analytical review. J Gen Virol 1987; 68 (Pt 11):2729-2740.
9. Vesikari T, Karvonen A, Korhonen T et.al. A randomized double-blind study of the safety, transmissibility, and phenotypic and genotypic stability of cold-adapted influenza virus vaccine (LAIV, FluMist®). Pediatr Infect Dis J 2006; 25:590-595.
10. Gruber WC. The role of live influenza vaccines in children. Vaccine 2002; 20:S66-S73.
11. Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998; 338:1405-1412.
12. Belshe RB, Gruber WC. Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. Pediatr Infect Dis J 2000; 19:S66-S71.
13. Bracco Neto H, Farhat CK, Tregnaghi MW et al. Efficacy and safety of one and two doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J 2009 (in press).
14. Belshe RB, Gruber WC, Mendelman PM et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000; 136:168-175.
15. Gaglani MJ, Piedra PA, Herschler GB et al. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med 2004; 158:65-73.
16. Halloran ME, Longini IM Jr, Gaglani MJ et al. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol 2003; 158:305-311.
17. Halloran ME, Piedra PA, Longini IM Jr et al. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine 2007; 25:4038-4045.
18. Tam JS, Capeding MR, Lum LC et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 2007; 26:619-628.
19. Jackson LA, Neuzil KM, Baggs J et al. Compliance with the recommendations for 2 doses of trivalent inactivated influenza vaccine in children less than 9 years of age receiving influenza vaccine for the first time: A Vaccine Safety Datalink study. Pediatrics 2006; 118:2032-2037.
20. Ashkenazi S, Vertruyen A, Aristegui J et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 25:870-879.
21. Fleming DM, Crovari P, Wahn U et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006; 25:860-869.
22. Belshe RB, Edwards KM, Vesikari T et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685-696.
23. FluMist®, Influenza Virus Vaccine Live, Intranasal. Full Prescribing Information, Gaithersburg, MD: MedImmune, 2007.
24. Nichol KL, Mendelman PM, Mallon KP et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: A randomized controlled trial. JAMA 1999; 282:137-144.
25. Bridges CB, Thompson WW, Meltzer MI et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 2000; 284:1655-1663.
26. Treanor JJ, Kotloff K, Betts RF et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 1999; 18:899-906.
27. Ohmit SE, Victor JC, Rotthoff JR et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006; 355:2513-2522.
28. Boyce TG. Influenza vaccines. N Engl J Med 2007; 356:1172; author reply 1173.
29. Lin YP, Gregory V, Bennett M, Hay A. Recent changes among human influenza viruses. Virus Res 2004; 103:47-52.
30. Ohmit SE, Victor JC, Teich ER et al. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis 2008; 198:312-317.
31. Strickler JK, Hawksworth AW, Myers C, Irvine M, Ryan MA, Russell KL. Influenza vaccine effectiveness among US military basic trainees, 2005-06 season. Emerg Infect Dis 2007; 13:617-619.
32. de Villiers PJT, Greyling M, Taylor CM et al. Efficacy of a live, attenuated, influenza vaccine in South African adults aged 60years or older against community-acquired culture-confirmed influenza. Options for the Control of Influenza, 5th International Conference, October 7-11, 2003, Okinawa, Japan.
33. Data on File (Study D153-P516). Gaithersburg, MD: MedImmune, 2006.
34. Treanor JJ, Mattison HR, Dumyati G et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med 1992; 117:625-633.
35. Treanor JJ, Betts RF. Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects. Vaccine 1998; 16:1756-1760.
36. Gorse GJ, O'Connor TZ, Young SL et al. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: A VA cooperative study. Vaccine 2003; 21:2133-2144.
37. Gorse GJ, O'Connor TZ, Young SL et al. Impact of a winter respiratory virus season on patients with COPD and association with influenza vaccination. Chest 2006; 130:1109-1116.
38. Forrest BD, Pride MW, Dunning AJ et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008; 15:1042-1053.
39. Vesikari T, Fleming DM, Aristegui JF et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics 2006; 118:2298-2312.
40. Belshe RB, Gruber WC, Mendelman PM et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000; 181:1133-1137.
41. Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer PS, Wright PF. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994; 169:68-76.
42. Block SL, Reisinger KS, for the LAIV Study Group. Shedding and safety of live attenuated influenza vaccine in healthy subjects 6 to <60 months of age. Pediatric Academic Societies'Annual Meeting, May 2-6, 2008, Honolulu, HI.
43. Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5 to 49 years of age. Vaccine 2008; 26:4940-4946.
44. King JC Jr, Fast PE, Zangwill KM et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 2001; 20:1124-1131.
45. King JC Jr, Treanor J, Fast PE et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 2000; 181:725-728.
46. Levin MJ, Song LY, Fenton T et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine 2008; 26:4210-4217.
47. Horimoto T, Kawaoka Y. Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus. J Virol 1994; 68:3120-3128.
48. Jin H, Manetz S, Leininger J et al. Toxicological evaluation of live attenuated, cold-adapted H5N1 vaccines in ferrets. Vaccine 2007; 25:8664-8672.
49. Suguitan AL Jr, McAuliffe J, Mills KL et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 2006; 3:e360.
50. Chen H, Matsuoka Y, Swayne D et al. Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine 2003; 21:4430-4436.
51. Karron RA, Callahan K, Luke C et al. A live attenuated H9N2 influenza vaccine is well-tolerated and immunogenic in healthy adults. J Infect Dis 2008 (in press).
52. Joseph T, McAuliffe J, Lu B et al. A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. Virology 2008; 378:123-132.
53. Lum LCS, Forrest BD, The LAIV Concomitant Vaccine Study Group. Safety, efficacy, and immunogenicity of live attenuated influenza vaccine concurrently administered with a combination mumps, measles, and rubella vaccine. 26th Annual Meeting of the European Society for Paediatric Infectious Diseases, May 13-17, 2008, Graz, Austria.